Explore more publications!
Health Press Barbados
Got News to Share?

Health Press Barbados: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Press Barbados.

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on January 7, 2026

RadNet Expands to Southwest Florida with Acquisition of Radiology Regional
January 7, 2026

RadNet Expands to Southwest Florida with Acquisition of Radiology Regional

Indeterminate GlobeNewswire
ExamWorks Announces Strategic Leadership Transition Plan to Further Accelerate Long-Term Growth
January 7, 2026

ExamWorks Announces Strategic Leadership Transition Plan to Further Accelerate Long-Term Growth

Indeterminate GlobeNewswire
RadNet Names Four Leaders to Expanded Executive Roles
January 7, 2026

RadNet Names Four Leaders to Expanded Executive Roles

Indeterminate GlobeNewswire
Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical
January 7, 2026

Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical

Indeterminate GlobeNewswire
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies
January 7, 2026

DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies

Indeterminate GlobeNewswire
LIfT BioSciences Announces CEO Transition to Drive Next Phase of Growth with Neutrophil-based Therapies
January 7, 2026

LIfT BioSciences Announces CEO Transition to Drive Next Phase of Growth with Neutrophil-based Therapies

Indeterminate GlobeNewswire
AnalystView Market Insights: Healthcare Virtual Assistant Market to Grow at a 35.08% CAGR Through 2032, Reaching US$ 29.63 Billion, Led by Nuance Communications, Microsoft, and Amazon.com
January 7, 2026

AnalystView Market Insights: Healthcare Virtual Assistant Market to Grow at a 35.08% CAGR Through 2032, Reaching US$ 29.63 Billion, Led by Nuance Communications, Microsoft, and Amazon.com

Indeterminate GlobeNewswire
Is MEDVi a Trusted GLP-1 Supplier for 2026? What to Know Before Choosing a Telehealth Weight Loss Platform
January 7, 2026

Is MEDVi a Trusted GLP-1 Supplier for 2026? What to Know Before Choosing a Telehealth Weight Loss Platform

Indeterminate GlobeNewswire
Correction: JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
January 7, 2026

Correction: JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist

Indeterminate GlobeNewswire
Relation Announces Strategic Collaboration with Deerfield Management to Advance Novel Therapeutics
January 7, 2026

Relation Announces Strategic Collaboration with Deerfield Management to Advance Novel Therapeutics

Indeterminate GlobeNewswire
World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
January 7, 2026

World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor

Indeterminate GlobeNewswire
Basilea und Prokaryotics starten Zusammenarbeit zur Entwicklung eines neuartigen Breitband-Antipilzmittels für die Behandlung schwerer invasiver Infektionen
January 7, 2026

Basilea und Prokaryotics starten Zusammenarbeit zur Entwicklung eines neuartigen Breitband-Antipilzmittels für die Behandlung schwerer invasiver Infektionen

Indeterminate GlobeNewswire
Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections
January 7, 2026

Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections

Indeterminate GlobeNewswire
JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
January 7, 2026

JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist

Indeterminate GlobeNewswire
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
January 7, 2026

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Indeterminate GlobeNewswire
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
January 7, 2026

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Indeterminate GlobeNewswire
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 7, 2026

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Indeterminate GlobeNewswire
Best Peptides for Weight Loss 2026: Oral Wegovy Launch Expands GLP-1 Format Options as Telehealth Platforms Compare FDA-Approved vs Compounded Semaglutide Access
January 7, 2026

Best Peptides for Weight Loss 2026: Oral Wegovy Launch Expands GLP-1 Format Options as Telehealth Platforms Compare FDA-Approved vs Compounded Semaglutide Access

Indeterminate GlobeNewswire
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
January 7, 2026

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

Indeterminate GlobeNewswire
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
January 7, 2026

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions